Guardant Health Stock Alpha and Beta Analysis
| GH Stock | USD 48.12 1.14 2.43% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Guardant Health. It also helps investors analyze the systematic and unsystematic risks associated with investing in Guardant Health over a specified time horizon. Remember, high Guardant Health's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Guardant Health's market risk premium analysis include:
Beta 1.76 | Alpha 0.86 | Risk 4.24 | Sharpe Ratio 0.22 | Expected Return 0.92 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Guardant |
Guardant Health Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Guardant Health market risk premium is the additional return an investor will receive from holding Guardant Health long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Guardant Health. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Guardant Health's performance over market.| α | 0.86 | β | 1.76 |
Guardant Health expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Guardant Health's Buy-and-hold return. Our buy-and-hold chart shows how Guardant Health performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Guardant Health Market Price Analysis
Market price analysis indicators help investors to evaluate how Guardant Health stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Guardant Health shares will generate the highest return on investment. By understating and applying Guardant Health stock market price indicators, traders can identify Guardant Health position entry and exit signals to maximize returns.
Guardant Health Return and Market Media
The median price of Guardant Health for the period between Mon, Nov 18, 2024 and Sun, Feb 16, 2025 is 35.78 with a coefficient of variation of 17.42. The daily time series for the period is distributed with a sample standard deviation of 6.53, arithmetic mean of 37.46, and mean deviation of 5.42. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 7000 shares by Kumud Kalia of Guardant Health at 29.246 subject to Rule 16b-3 | 11/18/2024 |
2 | Disposition of 316 shares by Darya Chudova of Guardant Health subject to Rule 16b-3 | 11/29/2024 |
3 | Acquisition by Tariq Musa of 250 shares of Guardant Health subject to Rule 16b-3 | 12/13/2024 |
4 | Disposition of 94555 shares by Helmy Eltoukhy of Guardant Health subject to Rule 16b-3 | 12/31/2024 |
5 | Disposition of 2084 shares by Michael Bell of Guardant Health subject to Rule 16b-3 | 01/03/2025 |
6 | Guardant Health Inc Selected for National Cancer Institutes Vanguard Study | 01/07/2025 |
7 | Disposition of 3309 shares by Michael Bell of Guardant Health subject to Rule 16b-3 | 01/15/2025 |
8 | Disposition of 711 shares by Eagle Craig of Guardant Health at 34.76 subject to Rule 16b-3 | 01/17/2025 |
9 | Guardant Health Inc Secures Medicare Coverage for Guardant Reveal Test in Colorectal ... | 01/21/2025 |
10 | Guardant Healths Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program | 01/30/2025 |
11 | Disposition of 154 shares by Krognes Steve E. of Guardant Health subject to Rule 16b-3 | 01/31/2025 |
12 | Disposition of tradable shares by Joyce Meghan V. of Guardant Health subject to Rule 16b-3 | 02/04/2025 |
13 | Are Medical Stocks Lagging Guardant Health This Year | 02/06/2025 |
14 | Guardant Health Announces Debt Exchange Transactions | 02/07/2025 |
15 | Guardant Health Inc Announces Participation in Key Investor Conferences | 02/10/2025 |
16 | These 2 Medical Stocks Could Beat Earnings Why They Should Be on Your Radar | 02/13/2025 |
About Guardant Health Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Guardant or other stocks. Alpha measures the amount that position in Guardant Health has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | PTB Ratio | 17.18 | 13.78 | Dividend Yield | 0.002485 | 0.00221 |
Guardant Health Upcoming Company Events
As portrayed in its financial statements, the presentation of Guardant Health's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Guardant Health's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Guardant Health's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Guardant Health. Please utilize our Beneish M Score to check the likelihood of Guardant Health's management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Guardant Health
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Guardant Health Backtesting, Guardant Health Valuation, Guardant Health Correlation, Guardant Health Hype Analysis, Guardant Health Volatility, Guardant Health History and analyze Guardant Health Performance. For more detail on how to invest in Guardant Stock please use our How to Invest in Guardant Health guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Guardant Health technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.